Published Date: 06 Mar 2023
Diabetic retinopathy is a leading cause of vision loss, with diabetic retinopathy (DDR) representing the most severe form of...
Read Full NewsThe newly approved generic product is expected to perform like other high-quality glatiramer acetate generics, with differences confined mainly to the manufacturer and device, not mechanism or dosing.
Catch up on any of the neurology news headlines you may have missed in December 2025, compiled into 1 place by the NeurologyLive® team.
A recent trial reveals semaglutide's potential for neurological improvement in stroke patients, despite no overall functional recovery benefits.
Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point
Pulmonology in 2025: Year in Review
Q4 2025 Recap: Pulmonology News and Updates
Switching Therapists for Psychotherapy Offers No Advantage in MDD
1.
AI-based liquid biopsy shows promise for detecting brain cancer
2.
Obesity linked to subsequent neoplasms in childhood cancer survivors
3.
Reducing social media to an hour a day boosts young people's self-image.
4.
Prostate Cancer Treatment Associated With Long-Term Complications
5.
Olaparib-Abiraterone in mCRPCs Selected by Biomarkers Outperforms Each Agent by Itself.
1.
Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances
2.
Unlocking the Potential of Lymphocytes: Exploring the Role of These Immune System Cells
3.
Hope in Numbers: Understanding AML Leukemia Survival Rates and Emerging Therapies
4.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
5.
Refractory Iron Deficiency Anemia in a Young Adult: Diagnostic Challenges
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
3.
Current Scenario of Cancer- Q&A Session to Close the Gap
4.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation